Genmab A/S
GNMSFOTCHealthcare● Active
$249.45
$-21.15(-7.82%)
Market Cap$15.3B
P/E Ratio—
52W High$352
52W Low$198.51
Genmab A/S (GNMSF) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
GNMSF · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 7, 2026EPS Actual
$0.85
Est. $1.56 · -45.5%
Revenue
$0.90B
Est. $0.91B · -1.1%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 7, 2026
After Market Close
▼ Miss EPS▼ Miss Revenue
GNMSF reports quarterly as a OTC-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.21
Rev. $0.66B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.21
Rev. Est.$0.66B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | $3.44 | — | — | — | $1.09B | — |
| ▼ Q2 FY2026 | May 7, 2026 | $1.56 | $0.85 | -45.5% | $0.90B | $0.91B | -1.1% |
| ▼ Q1 FY2026 | Feb 17, 2026 | $2.81 | $0.51 | -81.8% | $1.06B | $1.07B | -0.8% |
| ▲ Q4 FY2025 | Nov 6, 2025 | $4.86 | $6.46 | +32.9% | $1.02B | $1.01B | +1.1% |
| ▲ Q3 FY2025 | Aug 7, 2025 | $3.99 | $5.42 | +35.8% | $0.92B | $0.96B | -3.3% |
| ▲ Q2 FY2025 | May 8, 2025 | $1.87 | $3.05 | +63.1% | $0.75B | $0.76B | -1.3% |
| ▲ Q1 FY2025 | Feb 12, 2025 | $0.47 | $5.70 | +1125.0% | $0.89B | $0.90B | -0.8% |
| ▼ Q4 FY2024 | Nov 6, 2024 | $3.19 | $2.85 | -10.7% | $0.82B | $0.13B | +540.7% |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
$3.44
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 7, 2026Miss
EPS Actual
$0.85
EPS Est.
$1.56
EPS Surpr.
-45.5%
Revenue
$0.90B
Q1 FY2026
Feb 17, 2026Miss
EPS Actual
$0.51
EPS Est.
$2.81
EPS Surpr.
-81.8%
Revenue
$1.06B
Q4 FY2025
Nov 6, 2025Beat
EPS Actual
$6.46
EPS Est.
$4.86
EPS Surpr.
+32.9%
Revenue
$1.02B
Q3 FY2025
Aug 7, 2025Beat
EPS Actual
$5.42
EPS Est.
$3.99
EPS Surpr.
+35.8%
Revenue
$0.92B
Q2 FY2025
May 8, 2025Beat
EPS Actual
$3.05
EPS Est.
$1.87
EPS Surpr.
+63.1%
Revenue
$0.75B
Q1 FY2025
Feb 12, 2025Beat
EPS Actual
$5.70
EPS Est.
$0.47
EPS Surpr.
+1125.0%
Revenue
$0.89B
Q4 FY2024
Nov 6, 2024Miss
EPS Actual
$2.85
EPS Est.
$3.19
EPS Surpr.
-10.7%
Revenue
$0.82B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $8.04 | $8.69 | $9.59 | 1 |
| Q3 FY2028 | $7.03 | $7.60 | $8.39 | 1 |
| Q2 FY2028 | $5.90 | $6.38 | $7.04 | 1 |
| Q1 FY2028 | $4.47 | $4.83 | $5.33 | 1 |
| Q4 FY2027 | $5.16 | $5.58 | $6.16 | 1 |
| Q3 FY2027 | $4.48 | $4.85 | $5.35 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $1.6B | $1.7B | $1.8B | 8 |
| Q3 FY2028 | $1.5B | $1.5B | $1.7B | 6 |
| Q2 FY2028 | $1.3B | $1.4B | $1.5B | 5 |
| Q1 FY2028 | $1.2B | $1.2B | $1.3B | 5 |
| Q4 FY2027 | $1.4B | $1.4B | $1.6B | 6 |
| Q3 FY2027 | $1.2B | $1.3B | $1.4B | 6 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 7, 2026 | -45.5% | $275.00 | $270.60 | -1.60% |
| ▼ Q1 FY2026 | Feb 17, 2026 | -81.8% | $300.00 | $297.25 | -0.92% |
| ▲ Q4 FY2025 | Nov 6, 2025 | +32.9% | $285.00 | $285.00 | +0.00% |
| ▲ Q3 FY2025 | Aug 7, 2025 | +35.8% | $216.31 | $216.31 | +0.00% |
| ▲ Q2 FY2025 | May 8, 2025 | +63.1% | $209.05 | $196.22 | -6.14% |
| ▲ Q1 FY2025 | Feb 12, 2025 | +1125.0% | $186.76 | $191.84 | +2.72% |
| ▼ Q4 FY2024 | Nov 6, 2024 | -10.7% | $220.28 | $225.80 | +2.51% |
| ▲ Q3 FY2024 | Aug 8, 2024 | +6.0% | $261.20 | $260.04 | -0.44% |
Q2 FY2026-1.60%
Report Date
May 7, 2026
EPS Beat/Miss
-45.5%
Price Before
$275.00
Price After
$270.60
Q1 FY2026-0.92%
Report Date
Feb 17, 2026
EPS Beat/Miss
-81.8%
Price Before
$300.00
Price After
$297.25
Q4 FY2025+0.00%
Report Date
Nov 6, 2025
EPS Beat/Miss
+32.9%
Price Before
$285.00
Price After
$285.00
Q3 FY2025+0.00%
Report Date
Aug 7, 2025
EPS Beat/Miss
+35.8%
Price Before
$216.31
Price After
$216.31
Q2 FY2025-6.14%
Report Date
May 8, 2025
EPS Beat/Miss
+63.1%
Price Before
$209.05
Price After
$196.22
Q1 FY2025+2.72%
Report Date
Feb 12, 2025
EPS Beat/Miss
+1125.0%
Price Before
$186.76
Price After
$191.84
Q4 FY2024+2.51%
Report Date
Nov 6, 2024
EPS Beat/Miss
-10.7%
Price Before
$220.28
Price After
$225.80
Q3 FY2024-0.44%
Report Date
Aug 8, 2024
EPS Beat/Miss
+6.0%
Price Before
$261.20
Price After
$260.04
Avg Beat Reaction-0.77%
Avg Miss Reaction-0.00%
Beat Rate5 / 8 quarters
Largest Move-6.14% (Q2 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: GNMSF ends December
Genmab A/S (GNMSF) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $0.85 — missing the analyst consensus of $1.56 by -45.5%. The next GNMSF earnings date is expected around September 1, 2026.
Each quarter, investors track GNMSF earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. GNMSF revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
GNMSF's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
GNMSF earnings · 5 questionsGenmab A/S's next earnings report is expected around September 1, 2026. GNMSF typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; GNMSF historically reports after market close (AMC).
GNMSF earnings datewhen is GNMSF earningsGNMSF next earnings datewhen does GNMSF report earningsGNMSF earnings calendar
▸ Source: FMP · Genmab A/S SEC filings · US GAAP · Genmab A/S SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026